245 related articles for article (PubMed ID: 30038216)
1. Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.
Patten DK; Corleone G; Győrffy B; Perone Y; Slaven N; Barozzi I; Erdős E; Saiakhova A; Goddard K; Vingiani A; Shousha S; Pongor LS; Hadjiminas DJ; Schiavon G; Barry P; Palmieri C; Coombes RC; Scacheri P; Pruneri G; Magnani L
Nat Med; 2018 Sep; 24(9):1469-1480. PubMed ID: 30038216
[TBL] [Abstract][Full Text] [Related]
2. Distinct Roles for BET Family Members in Estrogen Receptor α Enhancer Function and Gene Regulation in Breast Cancer Cells.
Murakami S; Li R; Nagari A; Chae M; Camacho CV; Kraus WL
Mol Cancer Res; 2019 Dec; 17(12):2356-2368. PubMed ID: 31551256
[TBL] [Abstract][Full Text] [Related]
3. The estrogen-regulated transcription factor PITX1 coordinates gene-specific regulation by estrogen receptor-alpha in breast cancer cells.
Stender JD; Stossi F; Funk CC; Charn TH; Barnett DH; Katzenellenbogen BS
Mol Endocrinol; 2011 Oct; 25(10):1699-709. PubMed ID: 21868451
[TBL] [Abstract][Full Text] [Related]
4. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
[TBL] [Abstract][Full Text] [Related]
5. A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer.
Zhu C; Li L; Zhang Z; Bi M; Wang H; Su W; Hernandez K; Liu P; Chen J; Chen M; Huang TH; Chen L; Liu Z
Mol Cell; 2019 Aug; 75(4):791-806.e8. PubMed ID: 31303470
[TBL] [Abstract][Full Text] [Related]
6. PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α-Positive Breast Cancer Cells.
Gadad SS; Camacho CV; Malladi V; Hutti CR; Nagari A; Kraus WL
Mol Cancer Res; 2021 Oct; 19(10):1688-1698. PubMed ID: 34158394
[TBL] [Abstract][Full Text] [Related]
7. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences.
Giulianelli S; Riggio M; Guillardoy T; Pérez Piñero C; Gorostiaga MA; Sequeira G; Pataccini G; Abascal MF; Toledo MF; Jacobsen BM; Guerreiro AC; Barros A; Novaro V; Monteiro FL; Amado F; Gass H; Abba M; Helguero LA; Lanari C
Int J Cancer; 2019 Oct; 145(7):1874-1888. PubMed ID: 30843188
[TBL] [Abstract][Full Text] [Related]
8. SIP1/NHERF2 enhances estrogen receptor alpha transactivation in breast cancer cells.
Meneses-Morales I; Tecalco-Cruz AC; Barrios-García T; Gómez-Romero V; Trujillo-González I; Reyes-Carmona S; García-Zepeda E; Méndez-Enríquez E; Cervantes-Roldán R; Pérez-Sánchez V; Recillas-Targa F; Mohar-Betancourt A; León-Del-Río A
Nucleic Acids Res; 2014 Jun; 42(11):6885-900. PubMed ID: 24771346
[TBL] [Abstract][Full Text] [Related]
9. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
[TBL] [Abstract][Full Text] [Related]
10. NHERF1, a novel GPER associated protein, increases stability and activation of GPER in ER-positive breast cancer.
Meng R; Qin Q; Xiong Y; Wang Y; Zheng J; Zhao Y; Tao T; Wang Q; Liu H; Wang S; Jiang WG; He J
Oncotarget; 2016 Aug; 7(34):54983-54997. PubMed ID: 27448983
[TBL] [Abstract][Full Text] [Related]
11. YY1 binds to the E3' enhancer and inhibits the expression of the immunoglobulin κ gene via epigenetic modifications.
Zhou X; Xian W; Zhang J; Zhu Y; Shao X; Han Y; Qi Y; Ding X; Wang X
Immunology; 2018 Dec; 155(4):491-498. PubMed ID: 30098214
[TBL] [Abstract][Full Text] [Related]
12. Regulation of TET2 gene expression and 5mC oxidation in breast cancer cells by estrogen signaling.
Zhu X; Xiong L; Lyu R; Shen Y; Liu L; Li S; Argueta C; Tan L
Biochem Biophys Res Commun; 2022 Jan; 589():240-246. PubMed ID: 34929447
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.
Joosten SEP; Gregoricchio S; Stelloo S; Yapıcı E; Huang CF; Yavuz K; Donaldson Collier M; Morova T; Altintaş UB; Kim Y; Canisius S; Moelans CB; van Diest PJ; Korkmaz G; Lack NA; Vermeulen M; Linn SC; Zwart W
Genome Res; 2024 May; 34(4):539-555. PubMed ID: 38719469
[TBL] [Abstract][Full Text] [Related]
14. NR2F2 Orphan Nuclear Receptor is Involved in Estrogen Receptor Alpha-Mediated Transcriptional Regulation in Luminal A Breast Cancer Cells.
Erdős E; Bálint BL
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168782
[TBL] [Abstract][Full Text] [Related]
15. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
17. Tumour suppressor TET2 safeguards enhancers from aberrant DNA methylation and epigenetic reprogramming in ERα-positive breast cancer cells.
Lyu R; Zhu X; Shen Y; Xiong L; Liu L; Liu H; Wu F; Argueta C; Tan L
Epigenetics; 2022 Oct; 17(10):1180-1194. PubMed ID: 34689714
[TBL] [Abstract][Full Text] [Related]
18. Analysis of estrogen-regulated enhancer RNAs identifies a functional motif required for enhancer assembly and gene expression.
Hou TY; Kraus WL
Cell Rep; 2022 Jun; 39(11):110944. PubMed ID: 35705040
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic analysis of enhancer sequences in the estrogen receptor transcriptional program.
Tabe-Bordbar S; Song YJ; Lunt BJ; Alavi Z; Prasanth KV; Sinha S
Commun Biol; 2024 Jun; 7(1):719. PubMed ID: 38862711
[TBL] [Abstract][Full Text] [Related]
20. A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation.
Korkmaz G; Manber Z; Lopes R; Prekovic S; Schuurman K; Kim Y; Teunissen H; Flach K; Wit E; Galli GG; Zwart W; Elkon R; Agami R
Nucleic Acids Res; 2019 Oct; 47(18):9557-9572. PubMed ID: 31372638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
